Sevelamer for Reducing Endotoxemia and Immune Activation
Condition(s):HIV-1 InfectionLast Updated:October 11, 2018Completed
Hide Studies Not Open or Pending
Condition(s):HIV-1 InfectionLast Updated:October 11, 2018Completed
Condition(s):CKD Stage 3b; CKD Stage 4Last Updated:August 7, 2018Unknown status
Condition(s):Dialysis; Cardiovascular Disease; Atherosclerosis; Inflammation; HyperphosphatemiaLast Updated:July 31, 2017Terminated
Condition(s):Endstage Renal DiseaseLast Updated:June 18, 2020Completed
Condition(s):Hyperparathyroidism; Chronic Kidney DiseaseLast Updated:November 1, 2016Completed
Condition(s):Renal Failure ChronicLast Updated:December 23, 2016Completed
Condition(s):Hyperphosphatemia; Chronic Kidney DiseaseLast Updated:July 25, 2016Completed
Condition(s):Chronic Kidney Disease; HyperphosphatemiaLast Updated:March 24, 2015Terminated
Condition(s):We Investigated the Relationship Between Plasma FGF23 Levels and Endothelial Dysfunction in a Sizable Series of Incident Stage 3-4 CKD Patients.Last Updated:July 22, 2011Completed
Condition(s):Chronic Renal FailureLast Updated:April 28, 2016Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.